Q4 2024 total revenues of $53.2 million, +17% compared to Q4 2023 Q4 2024 Fanapt® net product sales of $26.6 million, +18% compared to Q4 2023 Full year 2024 total ...

Q4 2024 Management View CEO Mihael Polymeropoulos highlighted strong revenue growth for Fanapt, driven by its launch for bipolar I disorder and increased new-to-brand prescriptions by over 160% ...

ADHD can shorten life expectancy by nearly a decade. Yet, many adults go undiagnosed. Here’s what women need to know.

Biohaven's NDA for Troriluzole was accepted by the FDA, potentially leading to approval in Q3 2025. Click here to find out ...

Before lithium became available to treat this potentially devastating illness, bipolar I sufferers experienced repeated ...

BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...